TDOC vs GERN Comparison

Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.